🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

10,225 results for “He” Clear

  1. Rivastigmine

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  2. Rivastigmine

    Atrium Therapeutics

    Parkinson's Disease

    approved small molecule terminated

    1 trial

  3. Rivastigmine transdermal patch

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  4. Roflumilast Cream 0.15%

    Arcutis Biotherapeutics

    ITCH

    approved small molecule active

    1 trial

  5. Ropivacaine

    The First People's Hospital of Lianyungang

    Radius Fractures

    approved small molecule completed

    1 trial

  6. Ropivacaine

    The First People's Hospital of Lianyungang

    End Stage Renal Disease (ESRD)

    approved small molecule active

    1 trial

  7. Ropivacaine B. Braun 10 mg/ml injektionsvätska, lösning

    The George Institute

    lumbar arthrodesis

    approved small molecule active

    1 trial

  8. Rosuvastatin

    Hospital Authority, Hong Kong

    Systemic Lupus Erythematosus

    approved small molecule active

    1 trial

  9. Rosuvastatin

    The First People's Hospital of Lianyungang

    Hyperlipidemia

    approved small molecule active

    1 trial

  10. Rosuvastatin (5mg，10mg，20mg)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carotid Atherosclerosis

    approved small molecule active

    1 trial

  11. Rucacuzumab plus standard therapy

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke AIS

    approved small molecule active

    1 trial

  12. Ruxolitinib

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    2 trials

  13. S-1

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial

  14. S-ketamine & Ropivacaine

    The First People's Hospital of Lianyungang

    Postoperative Analgesia

    approved small molecule active

    1 trial

  15. SALBUTAMOL

    United Therapeutics Europe Ltd

    CHRONIC OBSTRUCTIVE PULMONARY DISEASE

    approved small molecule completed

    1 trial

  16. SALINE, TRANEXAMIC ACID

    Disc Medicine

    Slipped capital femoral epiphysis (SCFE), Legg-Calvé-Perthes Disease (LCPD), Neuromuscular conditions, Secondary hip dysplasia, Developmental dysplasia of the hip (DDH)

    approved small molecule active

    1 trial

  17. SELPERCATINIB, SELPERCATINIB

    Eli Lilly Co.

    Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;

    approved small molecule active

    1 trial

  18. SEMAGLUTIDE, SEMAGLUTIDE, INSULIN GLARGINE, DAPAGLIFLOZIN

    Fondazione Telethon ETS

    type 2 diabetes

    approved small molecule active

    1 trial

  19. SGLT2 inhibitor

    The First People's Hospital of Lianyungang

    Type2 Diabetes

    approved small molecule active

    1 trial

  20. SILDENAFIL , LEVOTHYROXINE SODIUM

    The George Institute

    erectile function, hypothyroidism subclinic

    approved small molecule active

    1 trial

  21. SINECATECHINS

    The George Institute

    Anal high-grade squamous intraepithelial lesions (HSIL).

    approved small molecule active

    1 trial

  22. SPN-812 (600mg, QD)

    SUPERNUS PHARMACEUTICALS, INC.

    Healthy Lactating Women

    approved small molecule completed

    1 trial

  23. SULPIRIDE , QUETIAPINE , PERPHENAZINE , CLOTIAPINE , ZIPRASIDONE , HALOPERIDOL , SERTINDOLE , PALIPERIDONE , ZUCLOPENTHIXOL , CARIPRAZINE , LEVOMEPROMAZINE , LURASIDONE , BREXPIPRAZOLE , AMISULPRIDE , CLOZAPINE , CHLORPROMAZINE , RISPERIDONE , FLUPHENAZINE , PROMAZINE , ARIPIPRAZOLE , ASENAPINE , OLANZAPINE , FLUPENTIXOL

    Disc Medicine

    schizophrenia, schizoaffective disorder, schizophrenifom disorder

    approved small molecule active

    1 trial

  24. SUMATRIPTAN , GLYCERYL TRINITRATE , RIMEGEPANT

    The George Institute

    Migraine

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources